Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors
- 28 September 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (24) , 6226-6230
- https://doi.org/10.1016/j.bmcl.2006.09.024
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Crystal Structures of DPP-IV (CD26) from Rat Kidney Exhibit Flexible Accommodation of Peptidase-Selective InhibitorsBiochemistry, 2006
- Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetesExpert Opinion on Therapeutic Patents, 2005
- Synthesis of Purines and Other Fused Imidazoles from Acyclic Amidines and GuanidinesOrganic Letters, 2005
- The GLP?1 system as a therapeutic targetAnnals of Medicine, 2005
- GIP as a Potential Therapeutic Agent?Hormone and Metabolic Research, 2004
- Dipeptidyl Peptidase IV Inhibitors for the Treatment of DiabetesJournal of Medicinal Chemistry, 2004
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanismProceedings of the National Academy of Sciences, 2003
- GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes/Metabolism Research and Reviews, 2003
- Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cellsEndocrinology, 1992